Neuroendocrine Tumors – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Neuroendocrine Tumors – Pipeline Review, H1 2020’, provides an overview of the Neuroendocrine Tumors pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors

– The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their major and minor projects

– The report assesses Neuroendocrine Tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aadi Bioscience Inc

Advanced Accelerator Applications SA

Akeso Inc

AnHeart Therapeutics Inc

Aquestive Therapeutics Inc

Ascil Proyectos SL

AstraZeneca Plc

Beijing Foreland Pharma Co Ltd

Boehringer Ingelheim International GmbH

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Camurus AB

CanBas Co Ltd

Clarity Pharmaceuticals Pty Ltd

Crinetics Pharmaceuticals Inc

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Eli Lilly and Co

Enterome Bioscience SA

EpicentRx Inc

Esanex Inc

Esperance Pharmaceuticals Inc

Exelixis Inc

GEMoaB Monoclonals GmbH

HEC Pharm Co Ltd

Highlight Therapeutics SL

Hutchison MediPharma Ltd

Innovent Biologics Inc

INVENT Pharmaceuticals Inc

Ipsen SA

Jubilant DraxImage Inc

Karyopharm Therapeutics Inc

Lexicon Pharmaceuticals Inc

Lixte Biotechnology Holdings Inc

Mateon Therapeutics Inc

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

MimiVax LLC

Mina Therapeutics Ltd

Molecular Targeting Technologies Inc

Molecular Templates Inc

Nanovalent Pharmaceuticals Inc

Northwest Biotherapeutics Inc

Novartis AG

Oncoceutics Inc

Oncology Venture U.S. Inc

Ono Pharmaceutical Co Ltd

Orano Med LLC

Pfizer Inc

Pharma Mar SA

Pharmathen Global BV

Progenics Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

Regulaxis SAS

Rhizen Pharmaceuticals SA

Seneca Therapeutics Inc

Shanghai Junshi Bioscience Co Ltd

Sichuan Huiyang Life Science and Technology Corp

Strongbridge Biopharma plc

Suntec Medical (Taiwan) Inc

Taiho Oncology Inc

Tarveda Therapeutics Inc

Teclison Ltd

Trio Medicines Ltd

Vanquish Oncology Inc

Veana Therapeutics LLC

Vyriad Inc

Xencor Inc

Table of Contents

Table of Contents

Introduction

Neuroendocrine Tumors - Overview

Neuroendocrine Tumors - Therapeutics Development

Neuroendocrine Tumors - Therapeutics Assessment

Neuroendocrine Tumors - Companies Involved in Therapeutics Development

Neuroendocrine Tumors - Drug Profiles

Neuroendocrine Tumors - Dormant Projects

Neuroendocrine Tumors - Discontinued Products

Neuroendocrine Tumors - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Neuroendocrine Tumors, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Neuroendocrine Tumors – Pipeline by Aadi Bioscience Inc, H1 2020

Neuroendocrine Tumors – Pipeline by Advanced Accelerator Applications SA, H1 2020

Neuroendocrine Tumors – Pipeline by Akeso Inc, H1 2020

Neuroendocrine Tumors – Pipeline by AnHeart Therapeutics Inc, H1 2020

Neuroendocrine Tumors – Pipeline by Aquestive Therapeutics Inc, H1 2020

Neuroendocrine Tumors – Pipeline by Ascil Proyectos SL, H1 2020

Neuroendocrine Tumors – Pipeline by AstraZeneca Plc, H1 2020

Neuroendocrine Tumors – Pipeline by Beijing Foreland Pharma Co Ltd, H1 2020

Neuroendocrine Tumors – Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Neuroendocrine Tumors – Pipeline by BriaCell Therapeutics Corp, H1 2020

Neuroendocrine Tumors – Pipeline by Bristol-Myers Squibb Co, H1 2020

Neuroendocrine Tumors – Dormant Projects, H1 2020

Neuroendocrine Tumors – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Neuroendocrine Tumors, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports